- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04432493
Using Combined EEG and Non-invasive Brain Stimulation to Examine and Improve Reward Functioning in Opioid Use Disorder
The primary aims of this study are to identify impaired cognitive control in opioid use disorder (OUD) and subsequently to examine the effects of transcranial magnetic stimulation (TMS) on reward processing, as measured by the reward positivity (an electrophysiological signal) in people with OUD. To this end, the investigators will adopt a randomized sham-controlled trial to evaluate the efficacy of Ri-TMS on cognitive control in OUD.
The investigators hypothesize that Ri-TMS will be successful in modulating the reward positivity in opioid users in the active TMS condition.
Study Overview
Status
Conditions
Detailed Description
The design is primarily a randomized control-trial design, comparing the effects of placebo (sham) and active TMS stimulation on reward processing across two groups of participants - healthy controls and opioid users.
Participants will be asked to engage in a virtual T-maze task, a reward-based choice task that elicits robust reward positivities. During this task participants will receive simultaneous EEG/TMS, while they engage in the virtual T-maze decision making task, used in our previous reward positivity studies on SUDs. ERPs will be recorded throughout the T-Maze task, and the reward positivity will be measured as the difference in maximum amplitude between reward and no-reward feedback conditions.
The TMS coil will be positioned using a an Adept Viper s850 robotic arm (SmartMove, ANT Neuro, Enschede, The Netherlands), providing precise targeting of the predetermined left dorsolateral prefrontal (DLPFC) coordinate (< 10 mm from the scalp, orientated at a 45º angle). Participants in the active TMS condition will receive rTMS pulses throughout the duration of the T-Maze task, with a maximum of 2000 pulses delivered to each participant. Identical parameters will be applied to the SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
Newark, New Jersey, United States, 07102
- Rutgers University - Newark
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Native English speakers
- Males and Females aged 18-55 years old
- Ability to provide informed written or verbal consent
- Opioid dependent individuals (according to the Alcohol, Smoking and Substance Involvement Screening Test opioid dependence score), or
- Healthy controls with no history of significant substance use
Exclusion Criteria:
- Un-correctable visual impairment
- Uninterruptable central nervous system medication
- TMS contraindications (e.g., pregnancy, braces, history of seizures, metal implants).
- History of neurological or psychiatric illness
- Diagnosed learning disability
- History of significant head injury (loss of consciousness for more than five minutes)
- Substance abuse (Participants who score above 39.5 on the Global Continuum of Substance Risk scale of the Alcohol, Smoking and Substance Involvement Screening Test - controls only)
- Use of psychoactive or vasoactive medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active TMS - OUD
Participants in the opioid used disorder group (OUD) in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined DLFPC target for a total of 2000 pulses
|
rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC).
Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
|
Placebo Comparator: Sham TMS - OUD
Identical parameters will be applied to the opioid used disorder (OUD) SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation
|
Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition.
Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
|
Active Comparator: Active TMS - HC
Healthy Control (HC) participants in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined DLFPC target for a total of 2000 pulses
|
rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC).
Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
|
Sham Comparator: Sham TMS - HC
Identical parameters will be applied to the healthy control (HC) SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation
|
Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition.
Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reward Positivity
Time Frame: Day 0 (day of testing)
|
The reward positivity is an event-related brain potential, sensitive to reward feedback.
The reward positivity will be measured during the t-maze task, where participants will receive feedback on choices (Reward, No-reward).
Reward positivity amplitude will be determined by identifying the maximum absolute amplitude of the difference wave within a 200- to 400-ms window following feedback onset.
The reward positivity will be evaluated along front-central electrodes (Fz, FCz, Cz).
|
Day 0 (day of testing)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kathryn Biernacki, PhD, Rutgers University - Newark
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro2018002739
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-use Disorder
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
Brigham and Women's HospitalOhio State UniversityActive, not recruitingOpioid Dependence | Opioid Use | Opioid-use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
-
University of ZurichCompletedOpioid Use, Unspecified With Other Opioid-induced DisorderSwitzerland
Clinical Trials on Active repetitive transcranial magnetic stimulation (rTMS)
-
Albert Einstein Healthcare NetworkMassachusetts General Hospital; Weill Medical College of Cornell University; University... and other collaboratorsNot yet recruitingTraumatic Spinal Cord Injury | Tetraplegia/TetraparesisUnited States
-
University of ManitobaCompleted
-
University of AarhusCentral Denmark Region; Hammel Neurorehabilitation Centre and University Research...RecruitingConcussion, Mild | Post-Traumatic Headache | MTBI - Mild Traumatic Brain InjuryDenmark
-
VA Office of Research and DevelopmentNot yet recruitingDepression | Depressive Disorder, Major | Spinal Cord InjuriesUnited States
-
The University of Texas Health Science Center at...Laurel Ridge Treatment Center; The Consortium to Alleviate PTSDCompletedStress Disorders, Post-TraumaticUnited States
-
University of MinnesotaCompletedTreatment Resistant DepressionUnited States
-
Children's Hospital Medical Center, CincinnatiCompleted
-
Shanghai Mental Health CenterXuhui Mental Health CenterRecruitingSchizophrenia | Cognitive Impairment | Repetitive Transcranial Magnetic Stimulation | Negative Symptoms in Schizophrenia | Dorsolateral Prefrontal CortexChina
-
Hugo Massé-AlariePfizer; Canadian Institutes of Health Research (CIHR); The Canadian Pain SocietyCompletedChronic Low-back PainCanada